WHO-defined myelodysplastic syndrome with isolated del(5q) in 88 consecutive patients: Survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations

Leukemia

Volumn 24, Issue 7, 2010, Pages 1283-1289

  Patnaik, M M ^a   Lasho, T L ^a   Finke, C M ^a   Gangat, N ^a   Caramazza, D ^b   Holtan, S G ^a   Pardanani, A ^a   Knudson, R A ^a   Ketterling, R P ^a   Chen, D ^a   Hoyer, J D ^a   Hanson, C A ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

5q ; ferritin; iron; isocitrate dehydrogenase; prognosis

Indexed keywords

FERRITIN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; JANUS KINASE 2; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE 2, HUMAN; JAK2 PROTEIN, HUMAN; MPL PROTEIN, HUMAN;

5Q- SYNDROME; ADULT; AGED; ARTICLE; BONE MARROW; CANCER MORTALITY; CANCER SURVIVAL; CHROMOSOME DELETION; COMORBIDITY; CYTOGENETICS; FEMALE; FERRITIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; WORLD HEALTH ORGANIZATION; CELL TRANSFORMATION; CHROMOSOME 5; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; MYELODYSPLASTIC SYNDROME; PATHOLOGY; POLYMERASE CHAIN REACTION; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; HUMANS; ISOCITRATE DEHYDROGENASE; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTORS, THROMBOPOIETIN; SURVIVAL RATE; WORLD HEALTH ORGANIZATION;

EID: 77954658029     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.105     Document Type: Article

References (37)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361:1872-1885.
2. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974;251:437-438.
3. Holtan SG, Santana-Davila R, Dewald GW, Khetterling RP, Knudson RA, Hoyer JD et al. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era. Am J Hematol 2008;83:708-713.
4. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del (5q) including band q31. Leukemia 2004;18:113-119.
5. Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer 2009;115:5202-5209.
6. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-1465.
7. Mathew P, Tefferi A, Dewald GW, Goldberg SL, Su J, Hoagland HC et al. The 5q-syndrome: a single-institution study of 43 consecutive patients. Blood 1993;81:1040-1045.
8. Van den Berghe H. The 5q-syndrome. wScand J Haematol Suppl 1986;45:78-81.
9. Santana-Davila R, Holtan SG, Dewald GW, Ketterling RP, Knudson RA, Hanson CA et al. Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. Leuk Res 2008;32:407-411.
10. Santana-Davila R, Tefferi A, Holtan SG, Ketterling RP, Dewald GW, Knudson RA et al. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del (5q): clinicopathologic comparison of del (5q)-positive and-negative cases. Leuk Res 2008;32:1927-1930.
11. Dewald GW, Broderick DJ, Tom WW, Hagstrom JE, Pierre RV. The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders. Cancer Genet Cytogenet 1985;18:1-10.
12. Shaffer LG, Tommerup N. An International System for Human Cytogenetic Nomenclature. S Karger: Basel, Switzerland, 2005.
13. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472-3476.
14. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008;22:756-761.
15. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174:1149-1153.
16. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009;15:6002-6007.
17. Chen D, Hoyer JD, Ketterling RP, Tefferi A, Steensma DP, Holtan SG et al. Dysgranulopoiesis is an independent adverse prognostic factor in chronic myeloid disorders with an isolated interstitial deletion of chromosome 5q. Leukemia 2009;23:796-800.
18. Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 2008;22:1813-1817.
19. Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 2008;49:388-397.
20. Ingram W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 2006;20:1319-1321.
21. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008;22:1299-1307.
22. Sokol L, Caceres G, Rocha K, Stockero KJ, Dewald DW, List AF. JAK2 (V617F) mutation in myelodysplastic syndrome (MDS) with del (5q) arises in genetically discordant clones. Leuk Res 2010;34:821-823.
23. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010;362:369-370.
24. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058-1066.
25. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3: e270.
26. Schnittger S, Haferlach C, Beelen DW, Bojko P, Dengler R, Diestelrath A et al. Detection of three different MPLW515 mutations in 10.1% of all JAK2 V617 unmutated ET and 9.3% of all JAK2 V617F unmutated OMF: a study of 387 patients. ASH Annu Meet Abstr 2007;110:2546.
27. Vannucchi AM, Antonioli E, Pancrazzi A, Guglielmelli P, Di Lollo S, Alterini R et al. The clinical phenotype of patients with essential thrombocythemia harboring MPL 515W4L/K mutation. ASH Annu Meet Abstr 2007;110:678.
28. Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 2007;137:244-247.
29. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008;112:141-149.
30. Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G et al. Characteristics and clinical correlates of MPL 515W4L/K mutation in essential thrombocythemia. Blood 2008;112:844-847.
31. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-1812.
32. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225-234.
33. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010;207:339-344.
34. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010;70:447-452.
35. Pardanani A, Lasho T, Finke C, Mai M, McClure R, Tefferi A. IDH1 and IDH2 mutation analysis in chronic and blast phase myeloproliferative neoplasms. Leukemia 2010 (in press).
36. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N EnglJ Med 2005;352:549-557.
37. Gohring G, Giagounidis A, Busche G, Kreipe HH, Zimmermann M, Hellstrom-Lindberg E et al. Patients with del (5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol 2010;89:365-374.